Dasatinib is already approved against Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML), and in combination with CAR-T cells, it is expected to act by suppressing T-cell activation via inhibition of proximal T-cell receptor (TCR)-signalling kinases, such as Src, Fyn, and Lck [31]. Here, LCK is linked to chronic myelogenous leukemia, BCR-ABL1 positive.